- Olema Pharmaceuticals, Inc. (Olema Oncology) announced a **new clinical trial collaboration and supply agreement with Pfizer Inc.** to evaluate the combination of **palazestrant** and **atirmociclib** in patients with **ER+/HER2- metastatic breast cancer**.  **[1750284_0001750284-25-000007_olma-ex99_1.htm:0]** **[1750284_0001750284-25-000007_olma-20250902.htm:1]** 
- The collaboration involves a **Phase 1b/2 study** with approximately **35 patients**, anticipated to initiate in **H2 2025**.  **[1750284_0001750284-25-000007_olma-ex99_1.htm:0]** 
- Olema will lead the study, and Pfizer will supply atirmociclib, with **joint ownership of clinical data** and inventions, while Olema retains **full global commercial and marketing rights to palazestrant**.  **[1750284_0001750284-25-000007_olma-ex99_1.htm:0]** **[1750284_0001750284-25-000007_olma-20250902.htm:1]** 
- The study's results are intended to inform a **potential pivotal Phase 3 trial** for the combination in the frontline metastatic breast cancer setting.  **[1750284_0001750284-25-000007_olma-ex99_1.htm:0]**

Olema Pharmaceuticals Announces New Clinical Trial Agreement with Pfizer

- OMass Therapeutics has entered into an **exclusive collaboration and license agreement** with Genentech, a member of the Roche Group, for its preclinical oral small molecule program targeting inflammatory bowel disease.  **[1750284_f2c1bfcb87b84e298812278666ab6a5d_1]** 
- The collaboration leverages OMass’s Odyssion™ platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease.  **[1750284_f2c1bfcb87b84e298812278666ab6a5d_0]** **[1750284_f2c1bfcb87b84e298812278666ab6a5d_1]** 
- Under the terms of the agreement, OMass will receive an **upfront payment of $20 million**.  **[1750284_f2c1bfcb87b84e298812278666ab6a5d_0]** **[1750284_f2c1bfcb87b84e298812278666ab6a5d_1]** 
- OMass is also eligible for **more than $400 million in additional milestone payments** (preclinical, development, commercial, and net sales) and tiered royalties on net sales.  **[1750284_f2c1bfcb87b84e298812278666ab6a5d_0]** **[1750284_f2c1bfcb87b84e298812278666ab6a5d_1]**

Olema Pharmaceuticals (OLMA)